AON-D21 / Aptarion - LARVOL DELTA

Aptamer based immunotherapy: a potential solid tumor therapeutic. (PubMed, Front Immunol) - "This review provides an overview of the recent advances in aptamer-based technologies with specific key clinical trials involving AON-D21 and AM003. The use of aptamers is expanded by the development of SOMAmers, X-aptamers, and bioinformatics. To make aptamer-based drugs a major part of cancer treatment, future research should concentrate more on resolving existing issues and expanding their beneficial uses."

Journal • Review • Oncology • Solid Tumor

Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia. (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: Aptarion Biotech AG | N=100 ➔ 150 | Trial completion date: Jun 2025 ➔ Jun 2026 | Trial primary completion date: May 2025 ➔ May 2026

Enrollment change • Trial completion date • Trial primary completion date • Infectious Disease • Pneumonia • Respiratory Diseases

Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia. (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Aptarion Biotech AG | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumonia • Respiratory Diseases

Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia. (clinicaltrials.gov) - P2 | N=100 | Not yet recruiting | Sponsor: Aptarion Biotech AG

New P2 trial • Infectious Disease • Pneumonia • Respiratory Diseases • ELANE • IL6

Ascending Multiple Intravenous Doses of AON-D21 in Healthy Male Subjects. (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Aptarion Biotech AG | Recruiting ➔ Completed

Trial completion

Ascending Multiple Intravenous Doses of AON-D21 in Healthy Male Subjects. (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Aptarion Biotech AG | Trial completion date: Jun 2022 ➔ Nov 2022 | Trial primary completion date: Jun 2022 ➔ Nov 2022

Trial completion date • Trial primary completion date

Ascending Multiple Intravenous Doses of AON-D21 in Healthy Male Subjects. (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: Aptarion Biotech AG

New P1 trial